All News

A recent study looked at the financial effects that many survivors of childhood cancer face.

In a recent study, researchers were working on identifying different molecular targets to better provide personalized care to patients with ovarian cancer. To do this, they examined more than 4,000 tumor specimins.

A new drug may be on the way to treat patients with advanced melanoma, as the FDA granted LN-144, which is produced by Iovance Biotherapeutics, a fast track designation. The drug uses tumor-infiltrating lymphocyte (TIL) technology to bolster the body’s immune system to attack cancer cells.

A cancer diagnosis robs us of many things. For an avid traveler, its like a bird being trapped in a cage.

A breast cancer and melanoma survivor who also speaks and writes about clutter clearing shares some cancer clutter clearing tips.

Stress reduction is a vital part of breast cancer survivorship. Learn how one survivor incorporated the word

There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).

Jonathan E. Rosenberg, M.D., discusses the implications of the new treatment guidelines for muscle-invasive bladder cancer.

Coping with losses, one lesson at a time

Studies look at women with peripheral neuropathy after treatment for early-stage breast cancer

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

Although they bring devastation to the whole community hit, catastrophes, such as Tropical Storm Harvey and Hurricane Irma, introduce a new level of difficulty for patients who are being treated for cancer.

RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

Aromatase inhibitors cause unwanted side effects. More and more women are choosing not to take them, but is this a good idea?

Melanoma survivor offers help based on her own melanoma experience and reading.

Survivor shares that there is no shame to talk to a therapist about life’s difficulties, especially when those difficulties have included coping with a cancer diagnosis and the ongoing fear of recurrence.

David R. Gandara, M.D., discusses the latest immunotherapy advances in lung cancer, as well as the next steps toward optimizing the use of these agents.

Kymriah, a CAR T-cell therapy, was approved to treat certain pediatric and young adult patients who have acute lymphoblastic leukemia (ALL).

Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

Sometimes the person you share your life with can help save yours.

Cancer has a silver lining, too. Breast cancer and melanoma survivor shares hers.

It's not really over, when it's "over."

Oncology care centers in Tropical Storm Harvey’s path close down locations, provide off-site care and update patients via their websites and social media.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.

If you're a writer who has had cancer, you won't be running out of story ideas any time soon.

We can all learn some things from an extraordinary young man.

The flood in Texas is causing strife for thousands of people. But patients with cancer have additional stressors.